Impact of pharmacist intervention in preventing nephrotoxicity from vancomycin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 4, 2015, Pages 284-291

  Masuda, Nobutoshi ^a,b   Maiguma, Takayoshi ^b   Komoto, Atsushi ^b   Haruki, Yuto ^a   Sugiyama, Tetsuhiro ^a   Kondo, Sachiyo ^a   Teshima, Daisuke ^b  

^a Tsuyama Central Hospital   (Japan)

^b SHUJITSU UNIVERSITY   (Japan)

Author keywords

Nephrotoxicity; Pharmacist intervention; Trough concentration; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; INITIAL DOSAGE PLANNING; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT CARE PLANNING; PATIENT MONITORING; PATIENT RISK; PHARMACIST ATTITUDE; PHARMACIST INTERVENTION; PRESCRIPTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COOPERATION; DOSE CALCULATION; EVALUATION STUDY; HOSPITAL PHARMACY; INCIDENCE; ISOLATION AND PURIFICATION; JAPAN; KIDNEY DISEASES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHARMACIST; PROFESSIONAL STANDARD; PROGRAM EVALUATION; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCAL INFECTIONS; STATISTICAL MODEL; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHI-SQUARE DISTRIBUTION; COOPERATIVE BEHAVIOR; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HUMANS; INCIDENCE; JAPAN; KIDNEY DISEASES; LOGISTIC MODELS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT CARE TEAM; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; VANCOMYCIN;

EID: 84929461310     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202274     Document Type: Article

References (20)

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer A W, Levine D P, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and chidren. Clin Infect Dis. 2011; 52: 285-292.
2. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer A W, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003; 36: 53-59.
3. Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2012; 56: 5164-5170.
4. Gould FK, Brindle R, Chadwick PR, Fraise A P, Hill S, Nathwani D, Ridgway GL, Spry MJ, Warren RE; MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. 2009; 63: 849-861.
5. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66: 82-98.
6. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006; 130: 947-955.
7. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012; 32: 195-201.
8. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013; 57: 734-744.
9. Fernández de Gatta MD, Calvo M V, Hernández JM, Caballero D, San Miguel J F, Domínguez-Gil A. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther. 1996; 60: 332-340.
10. Ariano RE, Demianczuk RH, Danzinger RG, Richard A, Milan H, Jamieson B. Economic impact and clinical benefits of pharmacist involvement on surgical wards. Can J Hosp Pharm. 1995; 48: 284-289.
11. Cockcroft D W, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
12. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011; 55: 5475-5479.
13. Lodise T P, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49: 507-514.
14. R Core Team. R: a Language and Environment for Statistical Computing. Vienna: R foundation for Statistical Computing, 2013 (http://www.R-project.org).
15. Jeffres MN, Isakow W, Doherty JA, Micek S T, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007; 29: 1107-1115.
16. Horey A, Mergenhagen KA, Mattappallil A. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann Pharmacother. 2012; 46: 1477-1483.
17. McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011; 158: 422-426.
18. Blot S, Koulenti D, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, Roberts JA. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care. 2014; 18: R99.
19. Shen WC, Chiang YC, Chen H Y, Chen TH, Yu FL, Tang CH, Sue YM. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology (Carlton). 2011; 16: 697-703.
20. Lodise T P, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52: 1330-1336.